Brokerages expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to announce earnings per share of ($0.35) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Sarepta Therapeutics’ earnings. The highest EPS estimate is ($0.24) and the lowest is ($0.56). Sarepta Therapeutics reported earnings of ($1.58) per share in the same quarter last year, which would suggest a positive year over year growth rate of 77.8%. The firm is scheduled to report its next quarterly earnings results after the market closes on Thursday, March 1st.
On average, analysts expect that Sarepta Therapeutics will report full year earnings of ($0.80) per share for the current year, with EPS estimates ranging from ($0.96) to ($0.71). For the next financial year, analysts anticipate that the business will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.38) to ($0.29). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that cover Sarepta Therapeutics.
A number of equities analysts have weighed in on SRPT shares. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, December 25th. Zacks Investment Research lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, January 9th. Needham & Company LLC reiterated a “buy” rating on shares of Sarepta Therapeutics in a research report on Friday, October 27th. Finally, Barclays increased their target price on shares of Sarepta Therapeutics from $46.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $66.15.
In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the transaction, the director now directly owns 13,333 shares in the company, valued at $745,181.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 9.60% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in SRPT. Ameriprise Financial Inc. raised its stake in Sarepta Therapeutics by 25.3% in the second quarter. Ameriprise Financial Inc. now owns 42,489 shares of the biotechnology company’s stock valued at $1,432,000 after purchasing an additional 8,581 shares in the last quarter. New York State Common Retirement Fund raised its stake in Sarepta Therapeutics by 4.9% in the second quarter. New York State Common Retirement Fund now owns 55,500 shares of the biotechnology company’s stock valued at $1,871,000 after purchasing an additional 2,599 shares in the last quarter. Northern Trust Corp raised its stake in Sarepta Therapeutics by 3.4% in the second quarter. Northern Trust Corp now owns 629,504 shares of the biotechnology company’s stock valued at $21,221,000 after purchasing an additional 20,680 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in Sarepta Therapeutics by 0.8% in the second quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock valued at $3,703,000 after purchasing an additional 818 shares in the last quarter. Finally, Stifel Financial Corp raised its stake in Sarepta Therapeutics by 100.3% in the second quarter. Stifel Financial Corp now owns 26,766 shares of the biotechnology company’s stock valued at $901,000 after purchasing an additional 13,400 shares in the last quarter. 86.62% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2018/02/21/analysts-anticipate-sarepta-therapeutics-inc-srpt-to-announce-0-35-eps.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.